Mammographic Breast Density and Breast Cancer Molecular Subtypes: The Kenyan-African Aspect
Table 3
Relationship between MD and tumor subtype (overall and stratified by menopausal status) among women included in this study.
Clinical characteristic
n
(%)
Percent density (%)
Absolute dense area
Nondense area
Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted
Mean
95% CI
Mean
95% CI
Mean
95% CI
Mean
95% CI
Mean
95% CI
Mean
95% CI
All women
ER status
Negative
33
27
20.0
16.7
23.3
19.3
16.2
22.4
61.2
47.7
74.7
63.2
49.9
76.6
280.3
232.7
327.8
286.0
242.7
329.3
Positive
90
73
25.9
23.7
28.2
25.8
23.7
28.0
92.8
82.7
102.9
94.4
84.8
104.1
266.1
238.0
294.2
274.1
249.0
299.2
P value
0.04
0.02
0.01
0.01
0.73
0.76
Premenopausal women
ER status
Negative
9
21
24.5
17.5
31.6
25.0
16.7
33.4
73.6
44.1
103.1
63.3
31.0
95.6
249.2
178.4
320.0
216.4
140.7
292.1
Positive
33
79
32.5
28.3
36.8
32.2
27.7
36.7
103.4
85.0
121.8
104.8
85.0
124.6
205.4
171.7
239.1
209.7
174.5
244.8
P value
0.19
0.31
0.25
0.16
0.45
0.95
Postmenopausal women
ER status
Negative
24
30
18.4
14.9
22.0
17.0
13.8
20.1
57.3
42.4
72.3
64.4
50.5
78.4
293.6
233.6
353.5
336.8
283.5
390.2
Positive
57
70
22.5
20.0
25.0
22.9
20.6
25.3
87.2
75.1
99.2
88.6
78.0
99.3
305.4
265.7
345.2
304.5
271.5
337.5
P value
0.20
0.05
0.04
0.07
0.81
0.48
All women
PR status
Negative
40
33
22.0
18.9
25.2
22.4
19.2
25.5
65.0
52.3
77.7
71.4
58.2
84.5
250.9
210.1
291.7
259.2
221.6
296.9
Positive
83
67
25.4
23.0
27.7
24.8
22.6
27.1
93.5
82.9
104.1
92.7
82.6
102.7
279.3
249.4
309.2
285.6
259.0
312.2
P value
0.25
0.38
0.02
0.08
0.43
0.43
Premenopausal women
PR status
Negative
11
26
26.0
19.4
32.6
28.1
19.9
36.3
78.4
50.7
106.1
78.1
44.7
111.5
241.4
178.2
304.6
217.0
148.1
285.9
Positive
31
74
32.5
28.1
36.9
31.7
27.0
36.4
103.5
84.4
122.5
102.5
81.6
123.4
205.3
170.5
240.1
209.1
172.4
245.8
P value
0.27
0.59
0.31
0.40
0.50
0.92
Postmenopausal women
PR status
Negative
29
36
20.7
17.3
24.1
19.5
16.3
22.7
60.6
46.6
74.7
68.5
55.2
81.9
255.4
205.3
305.6
296.9
250.8
343.0
Positive
52
64
21.6
18.9
24.2
21.9
19.5
24.4
88.1
75.4
100.8
88.2
77.1
99.3
329.5
286.9
372.1
323.4
288.1
358.7
P value
0.77
0.41
0.05
0.12
0.13
0.53
All women
TNBC status
No
95
77
25.8
23.5
28.0
26.1
23.9
28.2
92.9
83.1
102.7
96.6
87.4
105.7
271.3
244.6
298.1
279.2
255.5
302.8
Yes
21
17
20.1
15.9
24.3
17.4
13.6
21.1
58.7
42.2
75.2
56.3
41.1
71.4
266.5
210.2
322.8
287.2
234.9
339.4
P value
0.11
0.01
0.02
<0.01
0.89
0.87
Premenopausal women
TNBC status
No
33
85
33.1
28.7
37.4
33.1
28.6
37.6
111.6
93.9
129.3
115.7
97.9
133.5
218.9
187.8
250.0
225.0
193.6
256.4
Yes
6
15
22.0
13.7
30.2
19.0
10.4
27.5
54.1
25.7
82.5
37.3
12.5
62.1
222.9
149.7
296.1
216.7
139.3
294.1
P value
0.12
0.07
0.04
0.01
0.98
0.85
Postmenopausal women
TNBC status
No
62
81
22.3
19.8
24.7
22.9
20.6
25.2
83.8
72.2
95.4
87.6
77.2
98.0
301.9
264.2
339.7
306.7
274.4
339.1
Yes
15
19
19.5
14.9
24.1
16.4
12.4
20.4
61.4
41.4
81.4
64.0
45.8
82.2
286.7
212.1
361.3
331.9
262.9
400.9
P value
0.46
0.07
0.19
0.13
0.78
0.66
All women
HER2 status
Negative
94
76
24.2
22.0
26.4
23.8
21.7
25.8
83.1
73.6
92.6
86.4
77.4
95.5
270.2
243.3
297.1
284.8
260.8
308.8
Positive
22
18
26.9
22.1
31.7
27.4
22.8
32.1
99.5
78.1
121.0
99.3
78.9
119.7
271.4
215.9
327.0
262.0
213.6
310.5
P value
0.49
0.32
0.33
0.43
0.99
0.55
djusted for age and BMI and additionally adjusted for menopausal status in analyses that included all women. BMI: body mass index; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor; TNBC: triple negative breast cancer; CI: confidence intervals.
